New perspectives in iron chelation therapy for the treatment of Parkinson's disease

• Published in: Neural regeneration research Vol. 14; no. 11; pp. 1905 - 1906
• Main Authors: Nunez, Marco, Chana-Cuevas, Pedro
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer India Pvt. Ltd 01.11.2019; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd; Faculty of Sciences, Universidad de Chile, Santiago, Chile%Movement Disorders Center, Universidad de Santiago de Chile, Santiago, Chile; Wolters Kluwer - Medknow; Wolters Kluwer Medknow Publications
• Subjects: Alzheimer's disease; Amyotrophic lateral sclerosis; Ataxia; Care and treatment; Central nervous system; Chelation therapy; Clinical trials; Death; Deferiprone; Disease; Dopamine; Huntington's disease; Hypoxia; Kinases; Nervous system; Neurodegeneration; Neurodegenerative diseases; Neurons; Parkinson disease; Parkinson's disease; Phenols (Class of compounds)
• ISSN: 1673-5374; 1876-7958
• DOI: 10.4103/1673-5374.259614

[...]at the onset of motor symptoms, the loss of dopaminergic fiber density in the dorsal putamen was found to be considerably larger compared to the loss of neuron bodies in the sustantia nigra (Grosch et al., 2016). M30 treatment also induces survival signaling factors such as protein kinase C, extracellular signal-regulated kinase 1/2, Akt and GSK-3β. [...]by chelating Fe, M30 has a large neuroprotective effect through stabilization of hypoxia-inducible factor-1α. If the capacity of iron chelators to produce neuritogenesis holds in in vivo treatments, the expected effect of iron chelation therapy will be a slow-down of the neurodegeneration process [Figure 1]B1. [...]if connections between damaged neurons in the substantia nigra and movement control centers in the striatum are reestablished, then a reverse of the neurodegenerative process is to be expected.